Consolidated Statement Of Income

Daito Pharmaceutical Co., Ltd. - Filing #7590192

Concept 2021-06-01 to
2022-05-31
2021-06-01 to
2022-05-31
2021-06-01 to
2022-05-31
2021-06-01 to
2022-05-31
2021-06-01 to
2022-05-31
2021-06-01 to
2022-05-31
2021-06-01 to
2022-05-31
2020-06-01 to
2021-05-31
2020-06-01 to
2021-05-31
2020-06-01 to
2021-05-31
2020-06-01 to
2021-05-31
2020-06-01 to
2021-05-31
2020-06-01 to
2021-05-31
2020-06-01 to
2021-05-31
Consolidated statement of income
Statement of income
Net sales
43,464,000,000 JPY
43,197,000,000 JPY
48,714,000,000 JPY
48,474,000,000 JPY
Cost of sales
32,005,000,000 JPY
32,652,000,000 JPY
37,917,000,000 JPY
38,765,000,000 JPY
Operating expenses
Selling, general and administrative expenses
4,905,000,000 JPY
4,565,000,000 JPY
4,883,000,000 JPY
4,591,000,000 JPY
Depreciation
152,000,000 JPY
133,000,000 JPY
132,000,000 JPY
114,000,000 JPY
Operating expenses
Operating expenses
Operating expenses - general
Remuneration for directors (and other officers)
113,000,000 JPY
113,000,000 JPY
Operating profit (loss)
6,553,000,000 JPY
5,979,000,000 JPY
5,908,000,000 JPY
5,111,000,000 JPY
Ordinary profit (loss)
6,729,000,000 JPY
6,240,000,000 JPY
6,067,000,000 JPY
5,342,000,000 JPY
Net sales
Gross profit (loss)
11,458,000,000 JPY
10,545,000,000 JPY
10,797,000,000 JPY
9,708,000,000 JPY
General and administrative expenses
Salaries
Operating expenses
Research and development expenses
1,749,000,000 JPY
1,609,000,000 JPY
2,032,000,000 JPY
1,902,000,000 JPY
Selling, general and administrative expenses
Bonuses
238,000,000 JPY
240,000,000 JPY
Extraordinary income
269,000,000 JPY
276,000,000 JPY
125,000,000 JPY
125,000,000 JPY
Other
7,000,000 JPY
JPY
Non-operating income
Interest income
0 JPY
5,000,000 JPY
0 JPY
1,000,000 JPY
Dividend income
55,000,000 JPY
143,000,000 JPY
63,000,000 JPY
147,000,000 JPY
Other
38,000,000 JPY
35,000,000 JPY
28,000,000 JPY
15,000,000 JPY
Non-operating income
205,000,000 JPY
288,000,000 JPY
197,000,000 JPY
270,000,000 JPY
Cost of sales
Extraordinary losses
278,000,000 JPY
255,000,000 JPY
318,000,000 JPY
360,000,000 JPY
Impairment losses
JPY
207,000,000 JPY
Non-operating expenses
Interest expenses
9,000,000 JPY
7,000,000 JPY
7,000,000 JPY
7,000,000 JPY
Other
3,000,000 JPY
3,000,000 JPY
3,000,000 JPY
3,000,000 JPY
Non-operating expenses
29,000,000 JPY
27,000,000 JPY
39,000,000 JPY
38,000,000 JPY
Profit (loss) before income taxes
6,720,000,000 JPY
6,262,000,000 JPY
5,873,000,000 JPY
5,107,000,000 JPY
Gross profit
Extraordinary income
Gain on sale of investment securities
246,000,000 JPY
246,000,000 JPY
4,000,000 JPY
4,000,000 JPY
Income taxes - current
2,213,000,000 JPY
1,989,000,000 JPY
1,805,000,000 JPY
1,496,000,000 JPY
Extraordinary losses
Loss on retirement of non-current assets
33,000,000 JPY
32,000,000 JPY
7,000,000 JPY
2,000,000 JPY
Income taxes - deferred
-120,000,000 JPY
-138,000,000 JPY
-89,000,000 JPY
-75,000,000 JPY
Income taxes
2,092,000,000 JPY
1,850,000,000 JPY
1,716,000,000 JPY
1,420,000,000 JPY
Profit (loss)
4,412,000,000 JPY
4,627,000,000 JPY
4,412,000,000 JPY
4,412,000,000 JPY
4,412,000,000 JPY
3,686,000,000 JPY
4,157,000,000 JPY
3,686,000,000 JPY
3,686,000,000 JPY
3,686,000,000 JPY
Profit (loss) attributable to non-controlling interests
-40,000,000 JPY
-89,000,000 JPY
Profit (loss) attributable to owners of parent
4,668,000,000 JPY
4,668,000,000 JPY
4,668,000,000 JPY
4,246,000,000 JPY
4,246,000,000 JPY
4,246,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
84,000,000 JPY
-258,000,000 JPY
Foreign currency translation adjustment
150,000,000 JPY
97,000,000 JPY
Remeasurements of defined benefit plans, net of tax
-41,000,000 JPY
-86,000,000 JPY
Other comprehensive income
194,000,000 JPY
-248,000,000 JPY
Profit attributable to
Comprehensive income
4,821,000,000 JPY
3,908,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
4,820,000,000 JPY
3,969,000,000 JPY
Comprehensive income attributable to non-controlling interests
1,000,000 JPY
-60,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.